BackgroundCheck.run
Search For

Neil R O'BrienLong Beach, CA

Related to:
Peggy O'Brien 76

Neil O'Brien Phones & Addresses

Long Beach, CA   

Pacific Palisades, CA   

Moreno Valley, CA   

Beverly Hills, CA   

Riverside, CA   

Work

Company: Plus concepts 1995 Position: Business consultant,

Education

School / High School: John F. Kennedy University- Orinda, CA
Get Report
Control this profile

Mentions for Neil R O'Brien

Neil O'Brien resumes & CV records

Resumes

Neil O'Brien Photo 25

Neil O'brien

Neil O'Brien Photo 26

Neil O'brien

Neil O'Brien Photo 27

Neil O'brien

Skills:
Microsoft Office
Neil O'Brien Photo 28

Neil O'brien

Neil O'Brien Photo 29

Neil O'brien

Location:
United States
Neil O'Brien Photo 30

Neil O'brien - Hughson, CA

Work:
PLUS CONCEPTS 1995 to 2000
BUSINESS CONSULTANT, PLUS BUILDING CONCEPTS Nov 1990 to 2000
PRESIDENT, A Plus Building Concepts Jan 1986 to 2000
Owner REALTY SERVICES, A+ PLUS BUILDING CONCEPTS Jun 1981 to 2000
BROKER/OWNER PROPERTY MANAGEMENT - Lafayette, CA 1997 to Jun 2003 PLUS CONCEPTS - Walnut Creek, CA Feb 1996 to Sep 1996
NATIONAL EVENT COORDINATOR GOLDEN HOMES DEVELOPMENT, INC Jul 1989 to Nov 1990
VICE PRESIDENT REALTY SERVICES, A+ PLUS BUILDING CONCEPTS - Walnut Creek, CA Aug 1983 to Aug 1989
INVESTMENT CONSULTANT BLUE CROSS OF NORTHERN CA - Oakland, CA Oct 1970 to Sep 1981
SR. ADMINISTRATIVE SYSTEMS ANALYST COMPUTER MICROGRAPHICS, INC - San Francisco, CA May 1967 to Sep 1970
BRANCH MANAGER

Publications & IP owners

Us Patents

Mocetinostat In Combination With Chemotherapy To Treat Rhabdomyosarcoma

US Patent:
2022028, Sep 8, 2022
Filed:
Mar 7, 2022
Appl. No.:
17/688603
Inventors:
- Oakland CA, US
Noah FEDERMAN - Los Angeles CA, US
Dennis Joseph SLAMON - Woodland Hills CA, US
Neil O'BRIEN - Culver City CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31/506
A61K 31/395
A61P 35/00
A61K 9/00
Abstract:
The present disclosure provides a method of using mocetinostat in combination with vinorelbine to treating a patient with rhabdomyosarcoma (RMS). The patient can be a child, an adolescent, or an adult having a locally advanced RMS, an unresectable RMS, a metastatic RMS, or a recurrent RMS.

Kras G12C Inhibitors And Uses Thereof

US Patent:
2022022, Jul 21, 2022
Filed:
May 20, 2020
Appl. No.:
17/612972
Inventors:
- Pasadena CA, US
- Culver City CA, US
- Oakland CA, US
Brendan M. O'Boyle - Monrovia CA, US
Corey M. Reeves - Los Angeles CA, US
Oliver C. Loson - Monrovia CA, US
Brian M. Stoltz - San Marino CA, US
Martina S. McDermott - Los Angeles CA, US
Neil A. O'Brien - Los Angeles CA, US
Dennis Slamon - Los Angeles CA, US
International Classification:
C07D 403/14
C07D 471/10
C07D 487/10
C07D 491/10
C07D 495/10
C07D 498/10
Abstract:
The invention relates to compounds of Formula I, and pharmaceutically acceptable salts thereof, and methods of making and using the same. The compounds of the invention are effective in inhibiting KRAS protein with a G12C mutation and are suitable for use in methods of treating cancers mediated, in whole or in part, by KRAS G12C mutation.

Prmt5 Inhibitors And Uses Thereof

US Patent:
2022019, Jun 23, 2022
Filed:
Mar 25, 2020
Appl. No.:
17/598152
Inventors:
- Pasadena CA, US
- Culver City CA, US
- Oakland CA, US
Brian M. Stoltz - San Marino CA, US
Michael D. Bartberger - Sherman Oaks CA, US
Steven J. Wittenberger - Sherman Oaks CA, US
Oliver C. Loson - Monrovia CA, US
Martina S. McDermott - Los Angeles CA, US
Neil A. O'Brien - Los Angeles CA, US
Dennis Slamon - Los Angeles CA, US
International Classification:
C07D 487/04
A61P 35/00
Abstract:
The present disclosure describes compounds of formulas (I)-(V) and methods of making the same. The compounds of the present disclosure are useful as inhibitors of PRMT5 activity and in methods of treating cancers and other diseases.

Claudin-6 Bispecific Antibodies

US Patent:
2022017, Jun 9, 2022
Filed:
Mar 20, 2020
Appl. No.:
17/441183
Inventors:
- Los Angeles CA, US
Martina S. McDermott - Los Angeles CA, US
Neil A. O'Brien - Los Angeles CA, US
Michael J. Palazzolo - Los Angeles CA, US
Dennis Slamon - Los Angeles CA, US
Erika Von Euw - Los Angeles CA, US
Peter Bowers - Los Angeles CA, US
International Classification:
C07K 16/28
A61P 35/00
Abstract:
The present disclosure provides bispecific antigen-binding proteins which bind to Claudin-6 (CLDN6) and a second antigen. In various aspects, the antigen-binding proteins bind to Extracellular Loop 2 (EL2) of the extracellular domain of CLDN6. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.

Mcl1 Inhibitors And Uses Thereof

US Patent:
2023011, Apr 13, 2023
Filed:
Oct 2, 2020
Appl. No.:
17/766147
Inventors:
- Pasadena CA, US
- Culver City CA, US
- Oakland CA, US
Kevin C. Yang - San Gabriel CA, US
Tristin E. Rose - Los Angeles CA, US
Justin A. Hilf - Los Angeles CA, US
Brian M. Stoltz - San Marino CA, US
Michael D. Bartberger - Sherman Oaks CA, US
Oliver C. Loson - Monrovia CA, US
Martina S. McDermott - Los Angeles CA, US
Neil A. O'Brien - Los Angeles CA, US
Dennis Slamon - Woodland Hills CA, US
International Classification:
C07D 513/04
C07D 417/14
C07D 471/04
A61P 35/00
Abstract:
The present disclosure provides compounds, such as compounds of Formula I, and compositions that are MCL1 inhibitors.

Claudin-6 Antibodies And Drug Conjugates

US Patent:
2023004, Feb 16, 2023
Filed:
Jun 22, 2022
Appl. No.:
17/846900
Inventors:
- Oakland CA, US
Martina S. McDermott - Los Angeles CA, US
Neil A. O'Brien - Los Angeles CA, US
Michael J. Palazzolo - Los Angeles CA, US
Dennis Slamon - Los Angeles CA, US
Erika Von Euw - Los Angeles CA, US
Peter Bowers - Los Angeles CA, US
International Classification:
C07K 16/28
A61K 47/65
A61K 47/68
A61P 35/00
G01N 33/574
Abstract:
The present disclosure provides antigen-binding proteins which bind to Claudin-6 (CLDN6). In various aspects, the antigen-binding proteins bind to Extracellular Loop 2 (EL2) of the extracellular domain of CLDN6. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.

Claudin6 Antibodies And Methods Of Treating Cancer

US Patent:
2020029, Sep 17, 2020
Filed:
Sep 18, 2018
Appl. No.:
16/648428
Inventors:
- Oakland CA, US
Dennis Slamon - Woodland Hills CA, US
Neil A. O'Brien - Los Angeles CA, US
Michael J. Palazzolo - Los Angeles CA, US
Erika Von Euw - Los Angeles CA, US
International Classification:
C07K 16/28
C12N 15/63
G01N 33/574
A61P 35/00
Abstract:
The present disclosure provides antigen-binding proteins which bind to Claudin-6 (CLDN6). In various aspects, the antigen-binding proteins bind to Extracellular Loop 2 (EL2) of the extracellular domain of CLDN6. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.

Possible Relatives

Cynthia D O'Brien  David R O'Brien  Deanna O'Brien  Dale J O'Brien  Deborah J O'Brien  Debra W O'Brien  Daniel D O'Brien  Neil W Johnson  Neil H Stanfield  Neil T White 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.